Please use this identifier to cite or link to this item:
|Title:||Spiramyin-loaded PLGA implants for the treatment of ocular toxoplasmosis : development, characterization, biocompatibility, and anti-toxoplasma activity.|
|Authors:||Tavares, Harley da Silva|
Cardoso, Jéssica Ferreira
Almeida, Tamires Cunha
Marques, Maria Betânia de Freitas
Mussel, Wagner da Nova
Lopes, M. C. P.
Oréfice, Rodrigo Lambert
Andrade, S. N.
Varotti, Fernando de Pilla
Silva, Glenda Nicioli da
Silva, Gisele Rodrigues da
|Citation:||TAVARES, H. da S. et al. Spiramyin-loaded PLGA implants for the treatment of ocular toxoplasmosis: development, characterization, biocompatibility, and anti-toxoplasma activity. Pharmazie, v. 76, p. 68-76, 2021. Disponível em: <https://www.ingentaconnect.com/contentone/govi/pharmaz/2021/00000076/f0020002/art00004>. Acesso em: 10 jun. 2021.|
|Abstract:||Ocular toxoplasmosis is the major cause of infectious posterior uveitis worldwide, inducing visual field defect and/or blindness. Despite the severity of this disease, an effective treatment is still lacking. In this study, spiramycin-loaded PLGA implants were developed aiming at the treatment of ocular toxoplasmosis. Implants were manufactured by a hot-molding technique, characterized by Fourier Transform Infrared Spectroscopy, X-Ray Diffraction, Differential Scanning Calorimetry, Scanning Electron Microscopy; evaluated in terms of ocular biocompatibility by immunofluorescence, flow cytometry, cell migration, Hen’s egg test-chorioallantoic membrane (HET-CAM) irritation test; and investigated in terms of in vitro efficacy against Toxoplasma gondii. Characterization techniques indicated that spiramycin was dispersed into the polymeric chains and both substances preserved their physical structures in implants. The HET-CAM test indicated that implants did not induce hemorrhage or coagulation, being non-irritant to the CAM. ARPE-19 cells showed viability by MTT assay, and normality in cell cycle kinetics and morphology, without stimulating cell death by apoptosis. Finally, they were highly effective against intracellular parasites without inducing human retinal pigment epithelial cell death. In conclusion, spiramycin-loaded PLGA implants represent a promising therapeutic alternative for the local treatment of ocular toxoplasmosis.|
|metadata.dc.rights.license:||This article is Open Access under the terms of the Creative Commons CC BY-NC-ND licence. Fonte: Die Pharmazie - An International Journal of Pharmaceutical Sciences <https://www.ingentaconnect.com/contentone/govi/pharmaz/2021/00000076/f0020002/art00004#>. Acesso em: 23 jul. 2021.|
|Appears in Collections:||DEFAR - Artigos publicados em periódicos|
Files in This Item:
|ARTIGO_SpiramyinLoadedPLGA.pdf||1,89 MB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.